

ISV ANNUAL CONGRESS, 22-24 OCTOBER 2023
THE SWISSTECH CONVENTION CENTER, LAUSANNE, SWITZERLAND
ORAL PROGRAM
SUNDAY 22 OCTOBER 2023

08:00-10:00	REGISTRATION		
09:00-10:00	WELCOME COFFEE Sponsored by <i>Valneva</i>		
10:00-10:10	OPENING SESSION (Auditorium B) WELCOME BY ISV PRESIDENT: Denise Doolan , <i>University of Queensland, Australia</i> CO-CHAIR REMARKS: Xavier Saelens , <i>VIB-Ghent University, Belgium</i> ; Linda Klavinskis , <i>Kings College London, United Kingdom</i> ; Ken Ishii , <i>University of Tokyo, Japan</i> ; Bruno Correia , <i>École Polytechnique Fédérale de Lausanne, Switzerland</i> ; Giuseppe Pantaleo , <i>Swiss Vaccine Research Institute, Switzerland</i>		
10:10-10:40	STANLEY PLOTKIN LECTURE: VACCINES 2050 (Auditorium B) Rino Rappuoli , <i>Biotechnopolo di Siena Foundation, Italy</i> Session Chair: Denise Doolan , <i>University of Queensland, Australia</i>		
10:40-11:55	PLENARY SESSION 1: STRUCTURE-BASED VACCINE DESIGN (Auditorium B) Session Chairs: Jason McLellan , <i>University of Texas, Austin</i> and Lakshmi Krishnan , <i>National Research Council Canada</i>		
10:40-11:05	Antibodies Against Global Infectious Diseases Erica Ollmann Saphire , <i>La Jolla Institute for Immunology, USA</i>		
11:05-11:30	Structure-Guided Coronavirus Vaccine Design David Vesler , <i>Washington University, USA</i>		
11:30-11:55	Mapping Polyclonal Antibody Responses by Cryo-Electron Microscopy Aleksander Antanasijevic , <i>École Polytechnique Fédérale de Lausanne, Switzerland</i>		
12:00-13:30	LUNCH Sponsored by <i>Vaxxas</i>		
12:30-13:30	BioNTech WORKSHOP – DEVELOPMENT OF mRNA-BASED MEDICINES (Room 5BC) Welcome & Introduction Annette Vogel , <i>Senior Director, Infectious Disease Vaccines, BioNTech</i> (12:30-12:33) Learnings on mRNA Mode of Action and Insights from Translational Science Robbert van der Most , <i>Vice President Translational Science, Infectious Diseases, BioNTech</i> (12:34-12:51) Clinical Application of BioNTech's mRNA Technology in Infectious Diseases Claudia Crowell , <i>Medical Expert Clinical Trials, Infectious Diseases, BioNTech</i> (12:52-13:09) Panel Discussion and Q&A Led by Annette Vogel (13:10-13:27) Summary and Close Annette Vogel (13:28-13:30)		
13:30-14:55	PLENARY SESSION 2: T CELL INDUCING VACCINES – A NEW RENAISSANCE FOR CANCER? (Auditorium B) Session Chairs: Linda Klavinskis , <i>Kings College London, United Kingdom</i> and Jeffrey Ulmer , <i>TechImmune LLC, USA</i>		
13:30-13:55	Development of Neoantigen Vaccines for Solid Tumors: Molecular Responses and Clinical Benefit in End-Stage Patients Karin Jooss , <i>Gritstone bio, Inc., USA</i>		
13:55-14:20	Use of Immunoepitidomics for the Development of Personalized Cancer Immunotherapy Michal Bassani-Sternberg , <i>Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland</i>		
14:20-14:55	TBC		
15:00-15:30	COFFEE BREAK Sponsored by <i>EuBiologics Co</i>		
15:30-17:30	(Auditorium B) CONCURRENT SESSION 1 PATTERN-RECOGNITION AND ADJUVANT MECHANISMS Session Chairs: Ken Ishii , <i>University of Tokyo, Japan</i> Karin Jooss , <i>Gritstone bio, Inc., USA</i>	(Room 4BC) CONCURRENT SESSION 2A mRNA VACCINES IN ACTION: IMMUNOGENICITY AND PROTECTIVE EFFICACY Session Chair: Anna-Lise Williamson , <i>University of Cape Town, South Africa</i>	(Room 5BC) CONCURRENT SESSION 3 ★BRIGHT SPARKS★ PhD STUDENTS x12 Session Chairs: Margaret Liu , <i>ProTherImmune, USA</i> David Weiner , <i>The Wistar Institute, USA</i>

15:30-15:55	Comparing Human and Murine Innate Immune Responses to mRNA Vaccination Eva Bartok, <i>Institute of Tropical Medicine, Antwerp, Belgium</i>	Modified mRNA Vaccine Protects Against Lassa Virus in the Guinea Pig Model Despite a Lack of Neutralizing Antibodies Alexander Bukreyev, <i>University of Texas Medical Branch at Galveston, USA</i>	Exploring Galsomes, an mRNA Based Nanovaccine, for Protection Against Intracellular Bacterial Infections Ilke Aernout, <i>Ghent University, Belgium</i> (15:30-15:40)
15:55-16:10	Mechanisms of IL-6 Mediated Suppression of Germinal Center Responses to Vaccines in Neonatal Mice Mustafa Akkoyunlu, <i>US Food and Drug Administration, USA</i>	Immune Mechanisms of a Trivalent mRNA Vaccine for Prevention of Genital Herpes Sita Awasthi, <i>University of Pennsylvania, USA</i>	Unmodified Rabies mRNA Vaccine Elicits High Cross-Neutralizing Antibody Titers and Diverse B Cell Memory Responses Rodrigo Arcoverde Cerveira da Silva, <i>Karolinska Institutet, Sweden</i> (15:40-15:50)
16:10-16:25	Leptospira Lipid A is a Potent Adjuvant that Induces Sterilizing Immunity Against Leptospirosis Syed Faisal, <i>National Institute of Animal Biotechnology, India</i>	Transient and Persisting Innate Cytokine Changes Associate with Adaptive Immunity after Repeated SARS-CoV-2 BNT162b2 mRNA Vaccinations Barbar Felber, <i>National Cancer Institute at Frederick, USA</i>	Development of a Modified Live Attenuated Influenza Virus (MLV) Vaccine Against H9N2 Influenza A Virus Flavio Carginin Faccin, <i>University of Georgia, USA</i> (15:50-16:00)
16:25-16:40	LNP-CpG ODN-Adjuvanted Varicella-Zoster Virus Glycoprotein E Induced Comparable Levels of Immunity with Shingrix™ in VZV-Primed Mice Cunbao Liu, <i>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, China</i>	CONCURRENT SESSION 2B PLANT-BASED VACCINES: CLINICAL IMPACT AND NEW TARGETS Session Chair: Ed Rybicki, <i>University of Cape Town, South Africa</i>	
		Clinical Trial Phase 1 of Plant-Produced COVID-19 Vaccine in Thailand Waranyoo Phoolcharoen, <i>Chulalongkorn University Bangkok Thailand / Baiya Phytopharm Co., Ltd, Thailand</i> (16:25-16:50)	
16:40-16:55	Sulfated Lactosyl Archaeol Archaeosomes: Effectively Enhancing Immune Responses to Viral Pathogens from SARS-CoV-2 to Rabbit Hemorrhagic Disease Virus Michael McCluskie, <i>National Research Council Canada, Canada</i>	Plant-Based Production of Highly Potent Anti-HIV Antibodies With Engineered Posttranslational Modifications Advaita Singh, <i>Council for Scientific and Industrial Research, South Africa</i> (16:50-17:05)	Helper lipids: impact on expression, immunogenicity, and stability of self-amplifying RNA lipid nanoparticle vaccines Beatriz Dias Barbieri, <i>Imperial College London, United Kingdom</i> (16:10-16:20)
16:55-17:10	Superior Mucosal B- and T-Cell Responses Against SARS-CoV-2 After Heterologous Intramuscular mRNA Prime/Intranasal Protein Boost Vaccination With a Combination Adjuvant Michael Schotsaert, <i>Icahn School of Medicine at Mount Sinai, USA</i>	Development of Plant-Produced African Horse Sickness Virus Diagnostic Reagents and a Candidate mRNA Vaccine Munyaradzi Tinarwo, <i>University of Cape Town, South Africa</i> (17:05-17:20)	Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology Rory Hills, <i>University of Oxford, United Kingdom</i> (16:20-16:30)
			Characterization of Heterologous Systemic Prime and Mucosal Boost Humoral Immune Responses to a SARS-CoV-2 Protein Subunit Vaccine Candidates in Mice Mariam Maltseva, <i>University of Ottawa, Canada</i> (16:30-16:40)
			Meningococci Outer Membrane Vesicles Adjuvanted by Aluminum Hydroxide or Cholera Toxin Subunit B: Functionality and Long-Term Assessment of the Immune Response Amanda Izeli Portilho, <i>Adolfo Lutz Institute, Brazil</i> (16:40-16:50)
			Flagellin-Adjuvanted Trivalent Mucosal Vaccine Inhibits Dysbiotic Bacteria-Induced Periodontitis in a Mixed Murine Ligature-Oral Gavage Model Vandara Loeurng, <i>Chonnam National University, South Korea</i> (16:50-17:00)

17:10-17:25	The Many Facets of ALFQ: A Robust Liposomal Vaccine Adjuvant and a Potential Therapeutic Agent Mangala Rao, <i>Walter Reed Army Institute of Research, USA</i>		Protective Human Monoclonal Antibodies to the Parainfluenza Virus 3 Hemagglutinin-Neuraminidase Protein are Dependent on Epitope Specificity Rose Miller, <i>University of Georgia, USA</i> (17:00-17:10)
			Nanoparticle Immunoadjuvant Complexes Augment Antigen-Specific Germinal Center Responses Nicholas Tursi, <i>The Wistar Institute, USA</i> (17:10-17:20)
17:30-20:00	POSTER SESSION 1		
18:00-20:00	WELCOME RECEPTION Sponsored by <i>EpiVax, Inc.</i>		

End of Day 1

MONDAY 23 OCTOBER 2023

08:00-08:30	MORNING COFFEE Sponsored by <i>GPN Vaccines</i>
08:30-09:00	KEYNOTE LECTURE: Will the Promise of Mucosal Vaccination Ever Materialise? <i>Peter Openshaw, Imperial College London, UK</i>
09:00-10:20	PLENARY SESSION 3: RSV VACCINES & OTHER RESPIRATORY VIRUS VACCINES (Auditorium B) Session Chairs: <i>Neil Almond, National Institute for Biological Standards and Control (NIBSC), USA</i> and <i>Ann Ginsberg, Bill & Melinda Gates Foundation, USA</i>
09:00-09:25	Application of Structure-Based Vaccine Design Principles to RSV <i>Jason McLellan, University of Texas, Austin, USA</i>
09:25-09:50	Development and Clinical Implementation of a Maternal RSV Vaccine Program <i>Kena Swanson, Pfizer, USA</i>
09:50-10:05	Development of a Broadly Cross-Reactive Vaccine Against Rhinoviruses <i>Sebastian Johnston, Imperial College, United Kingdom</i>
10:05-10:20	Towards a COVID-19 Vaccine to Protect Against SARS-CoV-2 Variants and Animal Sarbecoviruses Without Updating <i>Alexander Cohen, Caltech, USA</i>
10:20-10:45	COFFEE BREAK Sponsored By <i>Pfizer</i>
10:45-12:00	PLENARY SESSION 4: B CELL IMMUNOLOGY AND MEMORY FOR DURABLE PROTECTION (Auditorium B) Session Chairs: <i>Denise Doolan, University of Queensland, Australia</i> and <i>Xavier Saelens, VIB-Ghent University, Belgium</i>
10:45-11:10	B Cell Memory Development <i>David Tarlinton, Monash University, Australia</i>
11:10-11:35	Pre-Erythrocytic Malaria Vaccine Design <i>Hedda Wardemann, German Cancer Research Center</i>
11:35-12:00	Novel Approaches for “Universal” Influenza Vaccines <i>Garnett Kelsoe, Duke University, USA</i>
12:00-13:30	LUNCH Sponsored by <i>Sanofi</i>
12:00-13:30	EARLY CAREER RESEACH PROGRAM: MEET THE VACCINE EXPERTS FOR LUNCH (Office AB and CD)
12:30-14:00	SANOFI WORKSHOP (Room 5BC) Chair: <i>Adrian McDermott, Head of Vaccines Global Immunology Technology and Portfolio Innovations at Sanofi Vaccines</i> <i>Danilo Casimiro, Vaccines Chief Scientific Officer & Health of External Scientific Affairs (12:35-12:55)</i> Strategies for Accelerating Early Phase Vaccine Development Across Multiple Expression Platforms <i>Albane Mabro, Vaccines Scientist Drug Substance Engineer (12:55-13:15)</i> Antigen Design: A Good Beginning for a Better Ending <i>Bachra Rokbi, Head of Transversal Antigen Design (13:15-13:25)</i> Beyfortus RSV mAb –Innovation Case Study <i>Rolf Kramer, Global Medical – RSV (13:25-13:45)</i> Conclusion and Q&A (1345-1400)
13:30-15:00	POSTER SESSION 2
14:00-15:00	ISV ANNUAL GENERAL MEETING (OPEN TO ALL CONGRESS ATTENDEES) (Room 4BC)
15:00-15:50	PLENARY SESSION 5: VACCINES FOR THE WORLD (Auditorium B) Session Chairs: <i>Shan Lu, Worcester HIV Vaccine (WHV), USA</i> and <i>Anna-Lise Williamson, University of Cape Town, South Africa</i>
15:00-15:25	Rift Valley Fever: Harnessing Synergies in Human and Veterinary Vaccinology <i>George Warimwe, KEMRI-Wellcome Trust Research Programme, Kenya / University of Oxford, UK</i>
15:25-15:50	Typhoid Fever: Why Vaccines? Why Now? <i>Jacob John, Christian Medical College and Hospital, India</i>

15:50-16:30	COFFEE BREAK Sponsored by Kyuan Trade		
16:30-17:55	(Auditorium B) CONCURRENT SESSION 4 NEXT-GENERATION VACCINES-1 Session Chairs: Danilo Casimiro, <i>Sanofi, USA</i> Sarah Gilbert, <i>University of Oxford,</i> <i>United Kingdom</i>	(Room 4BC) CONCURRENT SESSION 5 ONE HEALTH: WHAT WE LEARN FROM ANIMAL VACCINES Session Chair: Anke Huckriede, <i>University Medical Center Groningen,</i> <i>The Netherlands</i>	(Room 5BC) CONCURRENT SESSION 6 GLOBAL VACCINE PLATFORMS IN COLLABORATION WITH THE GLOBAL VACCINE LEADING TECHNOLOGY CENTER (GVLTC) Session Chair: Joon Haeng Rhee, <i>Chonnam</i> <i>National University, South Korea</i>
16:30-16:55	Novel Oral Polio Vaccine Type 2 (nOPV2) Ilse De Coster, <i>University of Antwerp, Belgium</i>	Self-Amplifying mRNA Vaccines Against (Re-)Emerging Viral Diseases Gorben Pijlman, <i>Wageningen University,</i> <i>The Netherlands</i>	Latch Applicator: Novel Applicator System for Efficient Vaccination Using Dissolving Microneedles Hyungil Jung, <i>Yonsei University, South Korea</i> (16:30-16:55)
16:55-17:10	Bivalent Conjugate Vaccine: A Potential Approach to Combat Fentanyl-Adulterated Heroin Erwin Abucayon, <i>Henry M. Jackson Foundation,</i> <i>Walter Reed Army Institute of</i> <i>Research, USA</i>	RVx101 Vaccine Dramatically Dampens Inflammation and Preserves the Visual Axis in Mice Infected Ocularly with Herpes Simplex Virus (HSV)-1 Daniel Carr, <i>University of Oklahoma Health</i> <i>Sciences Center, USA</i>	Dendritic Cell-Targeted All-in- One Vaccine Shee Eun Lee, <i>Chonnam National University,</i> <i>South Korea</i> (16:55-17:20)
17:10-17:25	Epitope Mapping as a Guide to Dosing a Trivalent gC2, gD2, gE2 mRNA-LNP Vaccine for Preventing Genital HSV-2 in the Guinea Pig Model and Ongoing Human Trials Lauren Hook, <i>University of Pennsylvania</i> <i>Perelman School of Medicine, USA</i>	Structural Analysis of a Computationally Optimized H1 Influenza Hemagglutinin Vaccine Reveals Conserved Antibody Epitopes Kaito Nagashima, <i>University of Georgia, USA</i>	The SARS-CoV-2 Monoclonal Antibody Combination AZD5156 (Cilgavimab/AZD3152) Potently Neutralizes Historical and Emerging Variants Wade Blair, <i>AstraZeneca, USA</i> (17:20-17:35)
17:25-17:40	A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Broadly Protective mRNA Vaccine JCXH-221 Against SARS- CoV-2 Infection and Diseases Ngocdiep Le, <i>Immorna Biotherapeutics, Inc., USA</i>	An Influenza M2e Vaccine Provides Broad Protection Through Suppression of Cellular Virus Release Nikolai Petrovsky, <i>Flinders Medical Centre, Australia</i>	A Recombinant, Non-Replicating Oral Rotavirus Vaccine for The Developing World Gilad Doitsh, <i>Vaxart, Inc., USA</i> (17:35-17:50)
17:40-17:55	Broadly Neutralizing Antibody Lineage Specificities and Neutralization Dynamics Induced by Wildtype Wuhan SARS-CoV-2 Spike mRNA Vaccination in Nonhuman Primates Kevin Saunders, <i>Duke University School of Medicine,</i> <i>USA</i>	The Antigenic Landscape of Recent Human Influenza Virus N2 Neuraminidases Circulating in 2009-2017 João Paulo Portela Catani, <i>VIB-UGent Center for Medical</i> <i>Biotechnology, Belgium</i>	A High-Density Micro-Projection Array Patch (HD-MAP) to Improve Effectiveness of Seasonal and Pandemic Influenza Vaccines Megan Polidano, <i>Vaxxas Pty Ltd Australia</i> (17:50-18:05)
18:15-18:30	PICK UP FOR GALA DINNER		
19:00-22:30	GALA DINNER (TICKETS REQUIRED)		

End of Day 2

TUESDAY 24 OCTOBER 2023

08:00-08:30	MORNING COFFEE Sponsored by <i>SK Bioscience Co</i>		
08:00-08:45	CAREER DEVELOPMENT PROGRAM: VOICES FROM INDUSTRY (Room 5BC) Session Chairs: Manon Cox , <i>NextWaveBio, USA</i> and Jeffrey Ulmer , <i>TechImmune LLC, USA</i>		
08:55-10:10	PLENARY SESSION 6: VACCINES AGAINST EMERGING INFECTIOUS DISEASES (Auditorium B) Session Chairs: Michael Schotsaert , <i>Icahn School of Medicine at Mount Sinai, USA</i> and Manon Cox , <i>NextWaveBio, USA</i>		
08:55-09:20	Preparing for Disease X – The 100 Day Mission Melanie Saville , <i>Coalition of Epidemic Preparedness Innovations (CEPI), UK</i>		
09:20-09:45	Developing Vaccines from a One Health Perspective Ab Osterhaus , <i>Stiftung Tierärztliche Hochschule Hannover (TiHo), Germany</i>		
09:45-10:10	Update to Valneva’s Live-Attenuated, Single-Dose Chikungunya Virus Vaccine Candidate (VLA1553): Antibody Persistence of VLA1553 in Adults Aged 18 Years and Above Susanne Eder-Lingelbach , <i>Valneva, Austria</i>		
10:10-10:40	COFFEE BREAK Sponsored by <i>CanSinoBIO</i>		
10:40-11:55	PLENARY SESSION 7: COVID-19 VACCINES (Auditorium B) Session Chairs: Peter Openshaw , <i>Imperial College London, UK</i> and Kena Swanson , <i>Pfizer, USA</i>		
10:40-11:05	Correlates of Protection for COVID-19 Vaccines Dan Barouch , <i>Harvard Medical School, USA</i>		
11:05-11:30	Development of Vaccines for COVID-19 Mina Yamamoto , <i>Shionogi & Co., Ltd., Japan</i>		
11:30-11:55	COVID-19 Vaccine Development; Lessons from South Korea Manki Song , <i>International Vaccine Institute (IVI), Korea</i>		
12:00-13:00	LUNCH Sponsored by <i>AstraZeneca</i>		
13:00-15:05	(AUDITORIUM B) CONCURRENT SESSION 7: NEXT GENERATION VACCINES-2 Session Chairs: Adrian McDermott , <i>NIAID, USA</i> Soumya Badrinath , <i>Novartis, USA</i>	(Room 4BC) CONCURRENT SESSION 8: VACCINE TECHNOLOGY PLATFORMS Session Chairs: Yvonne Genzel , <i>Max-Planck- Institute, Germany</i> Lars Frelin , <i>Karolinska Institutet, Sweden</i>	(Room 5BC) CONCURRENT SESSION 9: ★BRIGHT SPARKS★ EARLY CAREER POSTDOCS x12 Session Chairs: David Weiner , <i>The Wistar Institute, USA</i> Margaret Liu , <i>ProTherImmune, USA</i>
13:00-13:15	HIV-1 Envelope Glycoprotein Structure-Based Vaccine Design, Development and Immunogenicity Richard Wyatt <i>Scripps Research Institute, USA</i>	Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus Yield Yvonne Genzel <i>Max-Planck-Institute, Germany</i> (13:00-13:25)	Approaches to Rapidly Determine Adenoviral Vector Infectious Particles Zakia Alhareth <i>University of Oxford, United Kingdom</i> (13:00-13:10)
13:15-13:30	Mutation-Guided Vaccine Design: A Process for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction Kevin Wiehe <i>Duke University, USA</i>	The Need for a Serotype-Independent Pneumococcal Vaccine Tim Hirst <i>GPN Vaccines, Australia</i> (13:25-13:50)	HIV-1 Replicative Capacity Influences T-Cell Metabolism, Cytokine Induction and Viral Cell-to-Cell Transmission Omolara Baiyegunhi <i>Africa Health Research Institute, South Africa</i> (13:10-13:20)
13:30-13:45	Isolating an A32-like ADCC-Mediating Monoclonal Antibody from a Human Volunteer with a Polyvalent DNA Prime-Protein Boost HIV-1 Vaccine Shan Lu <i>Worcester HIV Vaccine (WHV), USA</i>	Towards a Highly Potent and Thermostable mRNA LNP Vaccine Platform Against Infectious Disease Stefaan De Koker <i>eTheRNA, Belgium</i> (13:50-14:05)	A Recombinant VSV Vaccine Induces Antibody-Independent Resistance in NHP Following Repeated SHIV Challenge. Joseph Jelinski <i>University of Texas Medical Branch, USA</i> (13:20-13:30)

13:45-14:00	HIV Vaccines Induce CD8⁺ T Cells with Low Antigen Receptor Sensitivity Mark Connors <i>HIV-Specific Immunity Section, NIAID, National Institutes of Health, USA</i>	Status and Progress on the Creation of an End-to-End mRNA Vaccine Development and Manufacturing Platform Accessible to LMIC Partners: A Report From the mRNA Hub Programme Caryn Fenner <i>Afrigen Biologics, South Africa</i> (14:05-14:20)	Molecular Adjuvant Adenosine Deaminase Enhances SARS-CoV-2 synDNA Vaccine-Induced Responses in Young and Aged Mice Ebony Gary <i>The Wistar Institute, USA</i> (13:30-13:40)
14:00-14:15	Next Generation Yellow Fever Vaccine Development Nathalie Mantel <i>Sanofi Pasteur Ltd, France</i>	Intranasal Immunization with Pneumococcal Capsular Polysaccharides-Displayed Outer Membrane Vesicles of Probiotic Escherichia Coli Elicits Systemic and Mucosal Immunity and Respiratory Protection Ryoma Nakao <i>National Institute of Infectious Diseases, Japan</i> (14:20-14:35)	Long-Term T-Cell Responses After SARS-CoV-2 mRNA Vaccination in Anti-CD20 Treated Patients Nelli Heikkila <i>University of Geneva, Switzerland</i> (13:40-13:50)
14:15-14:30	Development of IL-17A Peptide-Based Vaccine for Spondylarthritis in Animal Model and Human Phase 1 Clinical Trial Hironori Nakagami <i>Osaka University, Japan</i>	Development of Safe Recombinant Dengue Virus Vaccine Targeting Non-Structural Proteins Using Attenuated Vaccinia Virus DIs Strain Kyoko Tsukiyama-Kohara <i>Kagoshima University, Japan</i> (14:35-14:50)	Antibody and Cellular Immune Responses Following Fractional Versus Standard Booster Dose of COVID-19 Vaccination (Pfizer-BioNTech [BNT162b2]) in Mongolian Adults: A Randomised Control Trial Nadia Mazarakis <i>Murdoch Children's Research Institute, Australia</i> (13:50-14:00)
14:30-14:45	Sm-p80-Based Schistosomiasis Vaccine: Update on Human Clinical Trials in USA and Africa Afzal Siddiqui <i>Texas Tech University Health Sciences Center, USA</i>	Protective Chimeric RBD-Dimer Vaccines Against SARS-CoV-2 Kun Xu <i>Beijing Institutes of Life Science, Chinese Academy of Sciences, China</i> (14:50-15:05)	A Novel, Scalable, Multivalent, Self-Assembling Nanocage Vaccine Platform to Prevent Pancoronavirus Infections Sweety Samal <i>Translational Health Science and Technology Institute (THSTI), India</i> (14:00-14:10)
14:45-15:00	Broadly Protective COVID-19 mRNA Vaccine: Beyond the Spike Protein Haitao Hu <i>University of Texas Medical Branch, USA</i>		Nanocage-Mediated Delivery of a Ferritin-tPspA-FlaB Vaccine Induces Strong Protective Immune Responses Against Streptococcus Pneumoniae Tien Duc Nguyen <i>Chonnam National University, South Korea</i> (14:10-14:20)
			Establishing mRNA Capabilities in Latin-American Countries Luciano Chaneton <i>Sinergium Biotech, Argentina</i> (14:20-14:30)
			Using the 1st WHO International Standard of Anti-Chikungunya Virus Ig G to Establish a Robust Serological Correlate of Immune Protection Daniel Yara <i>Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom</i> (14:30-14:40)
			A Lipid Nanoparticle Templated Anti-Opioid Vaccine Zifu Zhong <i>Ghent University, Belgium</i> (14:40-14:50)
15:00-15:30	BREAK		


15:30-16:20	PLENARY SESSION 8: VACCINES AGAINST CHALLENGING PATHOGENS Session Chairs: Joon Haeng Rhee , <i>Chonnam National University, South Korea</i> and Denise Doolan , <i>University of Queensland, Australia</i>	(Auditorium B)
15:30-15:55	A Cross-Kingdom Vaccine Targeting Multidrug Resistant Healthcare-Associated Infections Ashraf S. Ibrahim , <i>Lundquist Institute for Biomedical Innovation, USA</i>	
15:55-16:20	T Cell Receptor Repertoires Associated with Control and Disease Progression following Mycobacterium tuberculosis Infection Munyaradzi Musvosvi , <i>University of Cape Town</i>	
16:20-16:40	ISV AWARDS CEREMONY	(Auditorium B)
16:40-17:00	ISV PAPER OF THE YEAR PRESENTATION A Vaccine Targeting Resistant Tumors by Dual T Cell Plus NK Cell Attack Soumya Badrinath , <i>Novartis, USA</i>	(Auditorium B)
17:00	CLOSING SESSION WITH INTRODUCTION TO THE 2024 ISV ANNUAL CONGRESS	(Auditorium B)

End of Program

Special Recorded Presentation Available on Virtual Platform

18 October 2023

Booster Confusion: When Are We Fully Protected Against Covid-19



Paul A. Offit, MD

Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania

*Recording Available to all Virtual and in-person Congress Participants.